|[January 10, 2013]
Research and Markets: Generic Growth Strategies
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/ksgr93/generic_growth)
has announced the addition of the "Generic
Growth Strategies - Market Driven by Impending Patent Cliff, Declining
R&D Productivity and Government Initiatives to Reduce Healthcare Costs"
report to their offering.
Market Driven by Impending Patent Cliff, Declining R&D Productivity and
Government Initiatives to Reduce Healthcare Costs
Generic Giants Strategize to Exploit Massive Patent Cliff Potential
Huge rewards and strong competition are prompting generic drug
manufacturers to closely examine the best way to maximize market share
as the industry patent cliff approaches its peak, states a new report
from business intelligence analysts GBI Research.
According to the firm's latest report*, the revenues of drugs subject to
patent expiration between 2013 and 2020 are valued at over US$100
billion, offering producers of generics and biosimilars a fantastic
opportunity to substantially bolster their own saes.
However, while the next few years hold great promise for these
companies, fierce competition exists not only from rival generics
manufacturers, but also from major pharmaceutical players looking to
maintain market dominance with Authorized Generics' (AG). In response,
generics firms are re-evaluating their approach to the market.
GBI Research states that companies such as Hospira are reaching out to
new locales in order to build a global presence, while targeting
governments looking to bring down healthcare costs. Exploiting
pharmaceutically underdeveloped economies may allow generics firms to
launch products first, challenging the intellectual property of
proprietary pharmaceutical majors.
Generics producers also hope to capitalize on expiring patents by
manufacturing complex generics that are difficult to reproduce. These
super generics have high barriers to entry, a greater price than most
other generics and incur greater Research and Development (R&D) costs;
however, there is significant potential for super generics within
specific therapeutic areas, such as cancer and conditions involving the
central nervous system.
GBI Research expects demand for high-quality generics to increase in the
future, as key drugs lose patent protection and governments are offered
opportunities to provide vital treatments at significantly reduced costs.
Key Topics Covered:
1.1 List of Tables
1.2 List of Figures
2 Generic Growth Strategies - Introduction
3 Generic Growth Strategies - Market Overview
4 Generic Growth Strategies - Regulatory Landscape
5 Generic Growth Strategies - Major Strategies
6 Generic Growth Strategies - Competitive Landscape
7 Generic Growth Strategies - Conclusion
8 Generic Growth Strategies - Appendix
- Teva Pharmaceutical Industries Limited
- Daiichi Sankyo
For more information visit http://www.researchandmarkets.com/research/ksgr93/generic_growth
[ Back To Technology News's Homepage ]